JP2005514941A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005514941A5 JP2005514941A5 JP2003562139A JP2003562139A JP2005514941A5 JP 2005514941 A5 JP2005514941 A5 JP 2005514941A5 JP 2003562139 A JP2003562139 A JP 2003562139A JP 2003562139 A JP2003562139 A JP 2003562139A JP 2005514941 A5 JP2005514941 A5 JP 2005514941A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- heat shock
- mammalian
- binding
- shock protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 101150013553 CD40 gene Proteins 0.000 claims 44
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims 44
- 239000012634 fragment Substances 0.000 claims 32
- 102000002812 Heat-Shock Proteins Human genes 0.000 claims 31
- 108010004889 Heat-Shock Proteins Proteins 0.000 claims 31
- 239000000427 antigen Substances 0.000 claims 22
- 102000036639 antigens Human genes 0.000 claims 22
- 108091007433 antigens Proteins 0.000 claims 22
- 230000002163 immunogen Effects 0.000 claims 11
- 210000000612 antigen-presenting cell Anatomy 0.000 claims 9
- 239000003795 chemical substances by application Substances 0.000 claims 9
- 239000003814 drug Substances 0.000 claims 9
- 210000004027 cell Anatomy 0.000 claims 8
- 101100125027 Dictyostelium discoideum mhsp70 gene Proteins 0.000 claims 4
- 101150031823 HSP70 gene Proteins 0.000 claims 4
- 150000001413 amino acids Chemical class 0.000 claims 4
- 101150052825 dnaK gene Proteins 0.000 claims 4
- 230000001965 increasing effect Effects 0.000 claims 4
- 210000004962 mammalian cell Anatomy 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 241000124008 Mammalia Species 0.000 claims 3
- 230000028993 immune response Effects 0.000 claims 3
- -1 IL-1α Proteins 0.000 claims 2
- 238000000338 in vitro Methods 0.000 claims 2
- 238000001727 in vivo Methods 0.000 claims 2
- 230000004048 modification Effects 0.000 claims 2
- 238000012986 modification Methods 0.000 claims 2
- 108091033319 polynucleotide Proteins 0.000 claims 2
- 102000040430 polynucleotide Human genes 0.000 claims 2
- 239000002157 polynucleotide Substances 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 230000035939 shock Effects 0.000 claims 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims 1
- 108010029697 CD40 Ligand Proteins 0.000 claims 1
- 102100032937 CD40 ligand Human genes 0.000 claims 1
- 208000035473 Communicable disease Diseases 0.000 claims 1
- 101000884675 Coxiella burnetii (strain RSA 493 / Nine Mile phase I) Co-chaperonin GroES Proteins 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims 1
- 108010002386 Interleukin-3 Proteins 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 108091034117 Oligonucleotide Proteins 0.000 claims 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 1
- 239000000074 antisense oligonucleotide Substances 0.000 claims 1
- 238000012230 antisense oligonucleotides Methods 0.000 claims 1
- 230000001363 autoimmune Effects 0.000 claims 1
- 239000003710 calcium ionophore Substances 0.000 claims 1
- 230000004700 cellular uptake Effects 0.000 claims 1
- 210000004443 dendritic cell Anatomy 0.000 claims 1
- CJAONIOAQZUHPN-KKLWWLSJSA-N ethyl 12-[[2-[(2r,3r)-3-[2-[(12-ethoxy-12-oxododecyl)-methylamino]-2-oxoethoxy]butan-2-yl]oxyacetyl]-methylamino]dodecanoate Chemical compound CCOC(=O)CCCCCCCCCCCN(C)C(=O)CO[C@H](C)[C@@H](C)OCC(=O)N(C)CCCCCCCCCCCC(=O)OCC CJAONIOAQZUHPN-KKLWWLSJSA-N 0.000 claims 1
- 239000013604 expression vector Substances 0.000 claims 1
- 230000036039 immunity Effects 0.000 claims 1
- 230000003053 immunization Effects 0.000 claims 1
- 238000002649 immunization Methods 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 229940127557 pharmaceutical product Drugs 0.000 claims 1
- 230000004044 response Effects 0.000 claims 1
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US34257001P | 2001-12-26 | 2001-12-26 | |
| US34388401P | 2001-12-27 | 2001-12-27 | |
| US37262002P | 2002-04-12 | 2002-04-12 | |
| US39934202P | 2002-07-29 | 2002-07-29 | |
| US41483402P | 2002-09-28 | 2002-09-28 | |
| PCT/US2002/041373 WO2003062262A2 (en) | 2001-12-26 | 2002-12-24 | Modulation of heat-shock-protein-based immunotherapies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005514941A JP2005514941A (ja) | 2005-05-26 |
| JP2005514941A5 true JP2005514941A5 (https=) | 2006-02-23 |
Family
ID=27617918
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003562139A Pending JP2005514941A (ja) | 2001-12-26 | 2002-12-24 | 熱ショックタンパク質に基づく免疫治療の調節 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20040071656A1 (https=) |
| EP (1) | EP1501860A4 (https=) |
| JP (1) | JP2005514941A (https=) |
| IL (1) | IL162747A0 (https=) |
| WO (1) | WO2003062262A2 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7420037B2 (en) * | 2003-02-13 | 2008-09-02 | Antigenics Inc. | Heat shock protein-based vaccines and immunotherapies |
| US7309491B2 (en) * | 2003-04-11 | 2007-12-18 | Antigenics Inc. | Heat shock protein-based vaccines and immunotherapies |
| EP1617804A4 (en) * | 2003-04-11 | 2007-07-25 | Antigenics Inc | IMPROVED VACCINE BASED ON HEAT SHOCK PROTEINS AND IMMUNOTHERAPIES |
| WO2005058821A1 (en) * | 2003-12-11 | 2005-06-30 | Schering Corporation | Inhibitors of hepatitis c virus ns3/ns4a serine protease |
| US7575738B2 (en) * | 2004-08-13 | 2009-08-18 | General Electric Company | Heat shock protein as a targeting agent for endothelium-specific in vivo transduction |
| EP2734231A1 (en) * | 2011-07-21 | 2014-05-28 | Biotech Tools S.A. | Dosage of dnak |
| EP2838547B1 (en) * | 2012-04-16 | 2019-09-04 | Lubrizol Advanced Materials, Inc. | Compounds for the treatment and/or care of the skin and/or mucous membranes and their use in cosmetic or pharmaceutical compositions |
| EA201792501A1 (ru) * | 2015-05-13 | 2018-10-31 | Эйдженус Инк. | Вакцины для лечения и профилактики рака |
| AU2018314269B2 (en) * | 2017-08-11 | 2022-12-08 | University Of Kentucky Research Foundation | Anti-neurodegenerative therapeutic, method of manufacture, and use |
| MA52363A (fr) | 2018-04-26 | 2021-03-03 | Agenus Inc | Compositions peptidiques de liaison à une protéine de choc thermique (hsp) et leurs méthodes d'utilisation |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5750119A (en) * | 1994-01-13 | 1998-05-12 | Mount Sinai School Of Medicine Of The City University Of New York | Immunotherapeutic stress protein-peptide complexes against cancer |
| EP1067194A1 (en) * | 1999-04-16 | 2001-01-10 | F. Hoffmann-La Roche Ag | Vectors containing a gene coding for CD40 and/or CD40L under the control of a cytokine-inducible promoter which is a human acute phase amyloid A gene promoter. Methods for their production and uses thereof |
| US20020086276A1 (en) * | 2000-12-28 | 2002-07-04 | Srivastava Pramod K. | Immunotherapeutic methods for extracorporeal modulation of CD36 and its ligands |
-
2002
- 2002-12-23 US US10/328,953 patent/US20040071656A1/en not_active Abandoned
- 2002-12-24 IL IL16274702A patent/IL162747A0/xx unknown
- 2002-12-24 WO PCT/US2002/041373 patent/WO2003062262A2/en not_active Ceased
- 2002-12-24 EP EP02806627A patent/EP1501860A4/en not_active Withdrawn
- 2002-12-24 JP JP2003562139A patent/JP2005514941A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Koffler et al. | Variable patterns of immunoglobulin and complement deposition in the kidneys of patients with systemic lupus erythematosus | |
| Zeltins et al. | Incorporation of tetanus-epitope into virus-like particles achieves vaccine responses even in older recipients in models of psoriasis, Alzheimer’s and cat allergy | |
| Ragupathi et al. | On the power of chemical synthesis: immunological evaluation of models for multiantigenic carbohydrate-based cancer vaccines | |
| US9205144B2 (en) | Identification of conserved peptide blocks in homologous polypeptides | |
| BR9917218A (pt) | Anticorpos monoclonais, antìgenos, e diagnósticoe terapia de doenças malignas | |
| JPS60500673A (ja) | 抗原活性を有するアミノ酸配列 | |
| JP2005514941A5 (https=) | ||
| JP2021504711A (ja) | 標的による干渉が抑制された抗薬物抗体アッセイ | |
| BRPI0511751A (pt) | usos médicos de conjugados veìculos de peptìdeos de tnf não-humano | |
| Ménoret et al. | Purification of multiple heat shock proteins from a single tumor sample | |
| AR033832A1 (es) | Un metodo ex vivo para diagnosticar una enfermedad autoinmune, anticuerpo, composicion de diagnostico que lo comprende, y usos del anticuerpo | |
| WO2000025722A3 (en) | ENHANCED VACCINES COMPRISING SELF AND NON-SELF IgE PORTIONS OR DIMERIC ANTIGENS | |
| Kalluri | Goodpasture syndrome | |
| Qian et al. | Immunogenicity of self-associated aggregates and chemically cross-linked conjugates of the 42 kDa Plasmodium falciparum merozoite surface protein-1 | |
| Jablonska et al. | Autoimmunity in psoriasis: relation of disease activity and forms of psoriasis to immunofluorescence findings | |
| Biswas et al. | The N-terminal fragment of GRP94 is sufficient for peptide presentation via professional antigen-presenting cells | |
| JPH02500857A (ja) | 膵島アミロイドポリペプチド | |
| BRPI0613525A2 (pt) | métodos para produzir uma composição imunogênica, para melhorar a imunogenicidade de uma composição, para intensificar a imunogenicidade de uma composição de vacina, e para determinar a quantidade de estruturas beta-cruzadas em uma composição de vacina, usos de estruturas beta-cruzadas, e de uma composição imunogênica, vacina de subunidade, e, composição imunogênica | |
| JP2024036461A (ja) | 自己集合ペプチド骨格 | |
| Sharif et al. | In silico design of CT26 polytope and its surface display by ClearColi™-derived outer membrane vesicles as a cancer vaccine candidate against colon carcinoma | |
| Kalacas et al. | Synthetic Peptide Antibodies via a Rational Approach Based on Disulfide‐Stabilized α‐Helical Peptides, for the Recognition of the Intrinsically Disordered Protein NUPR1 | |
| Li | In vitro reconstitution of heat shock protein–peptide complexes for generating peptide-specific vaccines against cancers and infectious diseases | |
| CN105504015A (zh) | 一种mhc-i类限制性抗肿瘤ctl表位肽 | |
| Zhang et al. | A mimotope of pre-S2 region of surface antigen of viral hepatitis B screened by phage display | |
| Lund et al. | Association of MBP peptides with Hsp70 in normal appearing human white matter |